Autologous Dendritic Cells Pulsed with Prostatic Acid Phosphatase (APC8015) for Patients with Hormone- Refractory Prostate Cancer with a Gleason Score ≤ 7

Infusion of dendritic cells pulsed with

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

✍ Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Jarisch, J.; Bowes, V.A.; Ragde, H.; Ro 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

## Background: A phase ii trial was conducted to assess the efficacy of infusions of dendritic cells (dc) and two hla-a2-specific psma peptides (psm-p1 and -p2). this report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who